Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 13M | 32.1% |
| Gross Profit | 8.3M | 77.3% |
| Cost of Revenue | 5.2M | 6.1% |
| Operating expense | 32M | 9.6% |
| Net Income | -17M | 4.2% |
| EBITDA | -19M | 2.4% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 135M | 9.8% |
| Total Liabilities | 70M | 0.4% |
| Total Equity | 66M | 18.6% |
| Shares Outstanding | 54M | 0.6% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 13M | 168.1% |
EPS
Financial Highlights for Spero Therapeutics in Q3 '24
Spero Therapeutics reported a revenue of 13M, which is a 32.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 8.3M, marking a 77.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 5.2M, a -6.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 32M, showing a 9.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -17M, showing a 4.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -19M, showing a 2.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Spero Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
